论文部分内容阅读
目的 研究检测尿I型胶原交联氨基末端肽 (NTx)监测抗骨吸收药物疗效的作用。方法 将 46名绝经后妇女随机分成治疗组 (阿仑磷酸钠 10mg/d ,6个月 )和对照组 (安慰剂 ,6个月 )。用ELISA法检测尿NTx值 ,双能X线骨密度仪测定腰椎骨密度。结果 治疗组和对照组的NTx和骨密度的改变率分别为 -5 1.64 %、5 %和 5 .16%、-2 .5 8%,治疗组的骨吸收指标均下降 ,以NTx下降最明显 ,近 5 1.4%(P <0 .0 0 1) ,对照组的NTx值却有所上升。结论 NTx是监测抗骨吸收药物疗效的敏感指标
Objective To investigate the effect of urinary type I collagen cross-linked amino-terminal peptide (NTx) in monitoring the anti-bone resorption drug efficacy. Methods 46 postmenopausal women were randomly divided into treatment group (alendronate 10mg / d, 6 months) and control group (placebo, 6 months). Urine NTx values were measured by ELISA and bone mineral density measured by dual energy X-ray absorptiometry. Results The change rates of NTx and BMD in the treatment group and the control group were -5 1.64%, 5% and 5.16%, -2.58%, respectively. The bone resorption index of the treatment group decreased and the NTx decreased most obviously , And nearly 51.4% (P <0.001), while the NTx value of the control group increased. Conclusion NTx is a sensitive indicator to monitor the efficacy of anti-bone resorption drugs